Abstract
Excellent/good levels of compliance were similar in the 3 groups (DFX 99%, DFP 95%; DFO 96%, P =0 .6). There were no significant differences in all 3 groups to maintain the patients without significant myocardial iron overload (global heart T2*≥20 ms) (DFX 98%; DFP 100%; DFO 98%; P=1.0). The percentage of patients that maintained a normal LVEF (>57%) was significantly lower in DFX (77%) versus DFP (100%) (P=0.018), it was no significantly different in DFX and DFO group (82%) (P=0.59). Among the patients with myocardial iron overload at baseline in all 3 groups, there was a significant improvement in the global heart T2* value and in the number of segment with a normal T2* value; only in the DFP group there was a significant improvement in the right global systolic function (+ 6.8% P =0.016). The improvement in the global heart T2* was significantly lower in the DFX versus the DFP group (P=0.0026), but it was not significantly different in the DFX versus the DFO group (mean difference global heart T2* 3.5±4.7 ms versus 8.8±8.6 ms and versus 3.7±5.5 ms, respectively; P=0.90) (Figure 1). The changes in the global systolic biventricular function were not significantly different among groups. Conclusions
Highlights
No data are available about the efficacy of the new oral one daily chelator deferasirox on cardiac iron and function versus deferiprone and desferrioxamine
A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
We evaluated prospectively the 193 thlassemia major (TM) patients who had been received one chelator alone between the 2 Magnetic Resonance (MR) scans
Summary
A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy. Alessia Pepe1*, Antonella Meloni, Giuseppe Rossi, Maria Chiara Dell’Amico, Anna Spasiano, Marcello Capra, Paolo Cianciulli, Vincenzo Caruso, Brunella Favilli, Eliana Cracolici, Aurelio Maggio, Massimo Lombardi. From 2011 SCMR/Euro CMR Joint Scientific Sessions Nice, France. From 2011 SCMR/Euro CMR Joint Scientific Sessions Nice, France. 3-6 February 2011
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.